AstraZeneca

British-Swedish pharmaceutical company

AZN London SE · home listing AZN NYSE AZN Nasdaq Stockholm ISIN GB0009895292 SEC CIK 901832 LEI PY6ZZQWO2IZFZC3IOL08
Follow AstraZeneca Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
EPS, diluted -
Revenue by quarter
$12.9B
$14.5B
Q2 24 Q2 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
$0$20B$40B$60BFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$58.7B$10.2B
FY24$54.1B$7B
FY23$45.8B$6B
FY22$44.4B$3.3B
FY21$37.4B$112M
FY20$26.6B$3.2B
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%25%50%75%100%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2581.9%23.4%17.4%
FY2481.1%18.5%13%
FY2382%17.9%13%
FY2272.1%8.5%7.4%
FY2166.8%2.8%0.3%
FY2080.1%19.4%12%
Free cash flowOperating cash flow minus capital expenditure
$0$5B$10B$15BFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$11.8B
FY24$9.9B
FY23$9B
FY22$8.7B
FY21$4.9B
FY20$3.8B
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$2B$4B$6BFY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25$5B$521M
FY24$4.6B$81M
FY23$4.5B-
FY22$4.4B-
FY21$3.9B-
FY20$3.6B-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • AstraZeneca
  • Healthcare median
−100%−75%−50%−25%0%25%FY20FY21FY22FY23FY24FY25
Show the numbers
YearAstraZenecaHealthcare median
FY2517.4%−30.8%
FY2413%−47%
FY2313%−58%
FY227.4%−80.4%
FY210.3%−71.9%
FY2012%−62.2%